Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: FDA reform

This article was originally published in The Tan Sheet

Executive Summary

FDA reform: CDER Division of OTC Drug Evaluation Director Debra Bowen, MD, to serve as agency contact for working groups assigned with developing implementation plans for provisions in the FDA Modernization Act pertaining to OTC labeling, completion of the sunscreen monograph and studies of mercury in nasal sprays. Contacts and mandatory deadlines for the many statutes of the act are listed in a Feb. 2 draft implementation plan. FDA created the working groups to determine whether provisions in the new act require rulemaking or are mandated ("The Tan Sheet" Jan. 19, p. 13). CFSAN Division of Programs and Enforcement Policy Director Elizabeth Campbell will head the working group on health claims and nutrient content claim petitions. The complete list of working group contacts is available at FDC Reports' home page at www.fdcreports.com...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088054

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel